Daewon Pharm (003220) - Net Assets
Based on the latest financial reports, Daewon Pharm (003220) has net assets worth ₩263.87 Billion KRW (≈ $178.82 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩606.37 Billion ≈ $410.93 Million USD) and total liabilities (₩342.50 Billion ≈ $232.11 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 003220 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩263.87 Billion |
| % of Total Assets | 43.52% |
| Annual Growth Rate | 8.06% |
| 5-Year Change | 33.75% |
| 10-Year Change | 91.43% |
| Growth Volatility | 3.07 |
Daewon Pharm - Net Assets Trend (2011–2024)
This chart illustrates how Daewon Pharm's net assets have evolved over time, based on quarterly financial data. Also explore 003220 asset base for the complete picture of this company's asset base.
Annual Net Assets for Daewon Pharm (2011–2024)
The table below shows the annual net assets of Daewon Pharm from 2011 to 2024. For live valuation and market cap data, see Daewon Pharm market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩284.58 Billion ≈ $192.85 Million |
+7.69% |
| 2023-12-31 | ₩264.26 Billion ≈ $179.09 Million |
+6.23% |
| 2022-12-31 | ₩248.77 Billion ≈ $168.58 Million |
+13.90% |
| 2021-12-31 | ₩218.40 Billion ≈ $148.01 Million |
+2.65% |
| 2020-12-31 | ₩212.77 Billion ≈ $144.19 Million |
+4.19% |
| 2019-12-31 | ₩204.22 Billion ≈ $138.39 Million |
+11.47% |
| 2018-12-31 | ₩183.20 Billion ≈ $124.15 Million |
+8.96% |
| 2017-12-31 | ₩168.13 Billion ≈ $113.94 Million |
+3.78% |
| 2016-12-31 | ₩162.01 Billion ≈ $109.79 Million |
+8.98% |
| 2015-12-31 | ₩148.66 Billion ≈ $100.75 Million |
+10.52% |
| 2014-12-31 | ₩134.51 Billion ≈ $91.16 Million |
+9.14% |
| 2013-12-31 | ₩123.25 Billion ≈ $83.53 Million |
+9.14% |
| 2012-12-31 | ₩112.92 Billion ≈ $76.53 Million |
+8.67% |
| 2011-12-31 | ₩103.92 Billion ≈ $70.42 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Daewon Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 26207671220000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩262.08 Billion | 95.20% |
| Other Components | ₩13.21 Billion | 4.80% |
| Total Equity | ₩275.28 Billion | 100.00% |
Daewon Pharm Competitors by Market Cap
The table below lists competitors of Daewon Pharm ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Surya Fajar Capital Tbk PT
JK:SFAN
|
$155.79 Million |
|
Groupe Sfpi
PA:SFPI
|
$155.83 Million |
|
Antony Waste Handling Cell Limited
NSE:AWHCL
|
$155.83 Million |
|
Orion Minerals Ltd
AU:ORN
|
$155.83 Million |
|
Habco Trans Maritima
JK:HATM
|
$155.64 Million |
|
China ZhengTong Auto Services Holdings Limited
F:ZA0
|
$155.60 Million |
|
Paragon Globe Bhd
KLSE:3611
|
$155.59 Million |
|
BioInvent International AB
ST:BINV
|
$155.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Daewon Pharm's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 266,198,938,600 to 275,284,566,430, a change of 9,085,627,830 (3.4%).
- Net income of 14,209,540,700 contributed positively to equity growth.
- Dividend payments of 6,358,815,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩14.21 Billion | +5.16% |
| Dividends Paid | ₩6.36 Billion | -2.31% |
| Other Changes | ₩1.23 Billion | +0.45% |
| Total Change | ₩- | 3.41% |
Book Value vs Market Value Analysis
This analysis compares Daewon Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.83x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.34x to 0.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩8019.68 | ₩10720.00 | x |
| 2018-12-31 | ₩8761.74 | ₩10720.00 | x |
| 2019-12-31 | ₩9785.93 | ₩10720.00 | x |
| 2020-12-31 | ₩10382.50 | ₩10720.00 | x |
| 2021-12-31 | ₩10335.27 | ₩10720.00 | x |
| 2022-12-31 | ₩11966.66 | ₩10720.00 | x |
| 2023-12-31 | ₩12558.89 | ₩10720.00 | x |
| 2024-12-31 | ₩12843.70 | ₩10720.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Daewon Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.16%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.38%
- • Asset Turnover: 1.03x
- • Equity Multiplier: 2.12x
- Recent ROE (5.16%) is below the historical average (9.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 9.10% | 6.79% | 0.99x | 1.35x | ₩-937.14 Million |
| 2012 | 8.55% | 6.96% | 0.94x | 1.31x | ₩-1.62 Billion |
| 2013 | 10.06% | 7.75% | 0.99x | 1.31x | ₩69.83 Million |
| 2014 | 11.75% | 8.64% | 1.01x | 1.35x | ₩2.34 Billion |
| 2015 | 11.94% | 8.19% | 1.11x | 1.31x | ₩2.88 Billion |
| 2016 | 12.54% | 8.41% | 1.12x | 1.33x | ₩4.10 Billion |
| 2017 | 6.39% | 4.05% | 1.17x | 1.35x | ₩-6.06 Billion |
| 2018 | 12.94% | 8.28% | 1.04x | 1.50x | ₩5.39 Billion |
| 2019 | 13.32% | 8.59% | 0.97x | 1.60x | ₩6.79 Billion |
| 2020 | 8.25% | 5.72% | 0.92x | 1.57x | ₩-3.75 Billion |
| 2021 | 3.19% | 1.97% | 0.82x | 1.96x | ₩-14.94 Billion |
| 2022 | 12.73% | 6.67% | 1.06x | 1.81x | ₩6.85 Billion |
| 2023 | 8.98% | 4.54% | 1.04x | 1.91x | ₩-2.70 Billion |
| 2024 | 5.16% | 2.38% | 1.03x | 2.12x | ₩-13.32 Billion |
Industry Comparison
This section compares Daewon Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $401,390,357,055
- Average return on equity (ROE) among peers: 0.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Daewon Pharm (003220) | ₩263.87 Billion | 9.10% | 1.30x | $155.71 Million |
| Dongwha Pharm.Co.Ltd (000020) | $252.93 Billion | 10.38% | 0.28x | $113.83 Million |
| Yuhan Corp. (000100) | $407.93 Billion | 10.79% | 0.55x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 2.42% | 0.28x | $59.61 Million |
| Yuyu Pharma (000220) | $69.50 Billion | 3.97% | 0.28x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $117.04 Billion | 1.10% | 0.32x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $169.10 Billion | -60.53% | 4.10x | $76.14 Million |
| Samil Pharm (000520) | $127.83 Billion | 1.30% | 1.90x | $127.90 Million |
| Donga Socio Holdings (000640) | $875.86 Billion | 17.02% | 0.60x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About Daewon Pharm
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemuls… Read more